- Two-year data from the two-year Phase 1b/2 trial of Tinlarebant (LBS-008) in adolescent Stargardt Disease (STGD1) to be presented
- A two-year global Phase 3 trial in adolescent STGD1 (the "DRAGON" study) and a two-year global Phase 3 trial in Geographic Atrophy (GA) patients (the "PHOENIX" study) are on-going
- Tinlarebant has been granted Fast Track and Rare Pediatric Disease Designations in the U.S. and Orphan Drug Designation in both the U.S. and Europe for STGD1, for which there are no FDA approved treatments
SAN DIEGO, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases that have significant unmet medical needs, today announced that the two-year data from the Phase 1b/2 trial of Tinlarebant (LBS-008) in adolescent STGD1 will be presented at the American Academy of Ophthalmology Annual Meeting (AAO 2023) being held November 3 – November 6, 2023, in San Francisco, CA.
Details of the presentation are as follows:
Title: A Phase 1b/2 Study of the Safety and Tolerability of Tinlarebant in Adolescent Stargardt Subjects
Session: PA050
Date and Time: Sunday, November 5, 2023; 3:57 PM to 4:04 PM PST
Location: Moscone Center, San Francisco
Presenting Author: Dr. John Grigg, MBBS
About Tinlarebant (a/k/a LBS-008)
Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to ...